A Phase II Single Institution Randomized Study Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplant
The purpose of this study is to determine the preferred injection site for G-CSF and GM-CSF,
which are cytokines, or growth factors. The doctor may also choose to use these growth
factors in combination with chemotherapy to increase the number of stem cells in the blood.
Both options are established and are effective in increasing the number of stem cells in the
Patients will receive one shot under the skin twice a day for approximately 12-15 days after
receiving chemotherapy through the time your cells are being collected. Patients will be
randomly assigned to receive growth factors administered either to their abdomen or to their
extremities. Both shots will always be given either in the abdomen or in the extremities.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The Total Number of CD34+ Cells Collected.
Edmund Waller, MD
Emory University Winship Cancer Institute
United States: Institutional Review Board
|Emory University Winship Cancer Institute||Atlanta, Georgia 30322|